These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4078699)

  • 1. Metabolic fate of phenprocoumon in humans.
    Toon S; Heimark LD; Trager WF; O'Reilly RA
    J Pharm Sci; 1985 Oct; 74(10):1037-40. PubMed ID: 4078699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of phenprocoumon metabolites in human urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.
    De Vries JX; Simon M; Zimmermann R; Harenberg J
    J Chromatogr; 1985 Mar; 338(2):325-34. PubMed ID: 3998021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine.
    de Vries JX; Völker U
    J Chromatogr; 1989 Aug; 493(1):149-56. PubMed ID: 2778004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary excretion of phenprocoumon and metabolites.
    de Vries JX; Raedsch R; Völker U; Walter-Sack I; Weber E
    Eur J Clin Pharmacol; 1988; 35(4):433-6. PubMed ID: 3197753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction.
    Edelbroek PM; van Kempen GM; Hessing TJ; de Wolff FA
    J Chromatogr; 1990 Sep; 530(2):347-58. PubMed ID: 2079509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
    Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE
    Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS.
    de Vries JX; Zimmermann R; Harenberg J
    Eur J Clin Pharmacol; 1986; 29(5):591-4. PubMed ID: 3956564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
    Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
    Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of wheat bran on the pharmacokinetics of phenprocoumon in normal volunteers.
    Kitteringham NR; Mineshita S; Ohnhaus EE
    Klin Wochenschr; 1985 Jun; 63(12):537-9. PubMed ID: 2993733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers.
    Haustein KO
    Biomed Biochim Acta; 1984; 43(12):1417-24. PubMed ID: 6534380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of phenprocoumon in the rat.
    Pohl LR; Haddock RE; Trager WF
    J Med Chem; 1975 May; 18(5):519-23. PubMed ID: 1151963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats.
    Schmidt W; Jähnchen E
    J Pharm Pharmacol; 1977 May; 29(5):266-71. PubMed ID: 17688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the coumarin anticoagulant phenprocoumon and metabolites in human plasma, urine and breast milk by high-performance liquid chromatography after solid-phase extraction.
    de Vries JX; Schmitz-Kummer E
    J Chromatogr B Biomed Appl; 1994 Apr; 655(1):63-71. PubMed ID: 8061835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stable isotope assay for phenprocoumon and its metabolites.
    Heimark LD; Trager WF
    Biomed Mass Spectrom; 1985 Feb; 12(2):67-71. PubMed ID: 3158358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The warfarin-sulfinpyrazone interaction: stereochemical considerations.
    Toon S; Low LK; Gibaldi M; Trager WF; O'Reilly RA; Motley CH; Goulart DA
    Clin Pharmacol Ther; 1986 Jan; 39(1):15-24. PubMed ID: 3943265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the metabolic profiles of R- and S-warfarin and R- and S-phenprocoumon as a probe to categorize the effect of inducing agents on microsomal hydroxylases.
    Porter WR; Wheeler C; Trager WF
    Biochem Pharmacol; 1981 Nov; 30(22):3099-104. PubMed ID: 7337727
    [No Abstract]   [Full Text] [Related]  

  • 19. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.